 Topotecan
"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
| Descriptor ID |
D019772
|
| MeSH Number(s) |
D03.132.151.850
|
| Concept/Terms |
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
- Hycamtamine
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Topotecan Monohydrochloride, (S)-Isomer
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
Hycamtin- Hycamtin
- SmithKline Beecham Brand of Topotecan Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in UAMS Profiles by year, and whether "Topotecan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2006 | 3 | 0 | 3 | | 2005 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Topotecan" by people in Profiles over the past ten years.
-
Tewari KS, Sill MW, Birrer MJ, Penson RT, Huang H, Moore DH, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.
-
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
-
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
-
Jyoti A, Fugit KD, Sethi P, McGarry RC, Anderson BD, Upreti M. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids. Sci Rep. 2015 Oct 15; 5:15236.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|